Analysis of Adverse Events Following Phenobarbital Administration for Pediatric Patients Categorized by One-Year Age Increments Using the U.S. Food and Drug Administration Adverse Event Reporting System

BackgroundOrgan and body development greatly varies in pediatric patients from year to year.Therefore, the incidence of each adverse event following phenobarbital (PB) administration would vary with age.However, in clinical trials, increasing the sample size of pediatric patients in each age group has been challenging.Therefore, previous studies were conducted by dividing pediatric patients into three or four age groups based on the development stage.Although these results were useful in clinical settings, information on adverse events that occurred at one-year age increments in pediatric patients could further enhance treatment and care. ObjectivesThis study investigated in one-year age increments the occurrence tendency of each adverse event following PB administration in pediatric patients. MethodsThis study used data obtained from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).Two inclusion criteria were set: (1) treatment with PB between January 2004 and June 2023 and (2) age 0-15 years.Using the cutoff value obtained using the Wilcoxon-Mann-Whitney test by the minimum pvalue approach, this study explored changes in the occurrence tendency of each adverse event in one-year age increments.At the minimum p-value of <0.05, the age corresponding to this p-value was determined as the cutoff value.Conversely, at the minimum p-value of ≥0.05, the cutoff value was considered nonexistent. ResultsThis study investigated all types of adverse events and explored the cutoff value for each adverse event.We identified 34, 16, 15, nine, five, five, eight, three, and eight types of adverse events for the cutoff values of ≤3/>3, ≤4/>4, ≤5/>5, ≤6/>6, ≤7/>7, ≤8/>8, ≤9/>9, ≤10/>10, and ≤11/>11 years, respectively. ConclusionsThis study demonstrated that adverse events requiring attention in pediatric patients varied with age.The findings help in the improvement of treatment and care in the pediatric clinical settings.